Epoetin Beta
- 1 January 2004
- journal article
- review article
- Published by Springer Nature in Drugs
- Vol. 64 (3) , 323-346
- https://doi.org/10.2165/00003495-200464030-00006
Abstract
Epoetin beta (NeoRecormon®) is a recombinant form of erythropoietin. It increases reticulocyte counts, haemoglobin (Hb) levels and haematocrit. EpoetiKeywords
This publication has 78 references indexed in Scilit:
- Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trialThe Lancet, 2003
- Human recombinant erythropoietin and quality of life: a wonder drug or something to wonder about?The Lancet Oncology, 2002
- Controlled multicentre study of the influence of subcutaneous recombinant human erythropoietin on anaemia and transfusion dependency in patients with ovarian carcinoma treated with platinum-based chemotherapyMedical Oncology, 1998
- Prevention of chemotherapy‐induced anemia by the use of erythropoietin in patients with primary malignant bone tumors (a double‐blind, randomized, phase III study)Transfusion, 1996
- Epoetin BetaDrugs, 1996
- Controversies in Selection of Epoetin DosagesDrugs, 1995
- Erythropoietin Overview-1993Blood Purification, 1994
- Is Recormon® less painful than Eprex® after subcutaneous administration?International Journal of Clinical Pharmacy, 1992
- Pain after subcutaneous injection of erythropoietin.BMJ, 1991
- Epoetin (Recombinant Human Erythropoietin)Drugs, 1989